Posters presented by Young Investigators (born in 1984 or after):
Investigations
Basic Studies
| CASALLAS VANEGAS Adriana | Mexico |
Conversion and reversion of JCV antibody serostatus and longitudinal evaluation in a Mexican Multiple Sclerosis population - ID81
|
| CASALLAS VANEGAS Adriana | Mexico | Efficacy of rituximab at different doses in Neuromyelitis Optica Spectrum Disease (NMOSD). Experience in patients of a tertiary level hospital in Mexico - ID83 View poster - Abstract - Poster presentation recording |
| CAVALIERE Carlo | Spain |
Analysis of retinal layers using SS-OCT registries for diagnosing multiple sclerosis - ID54
|
| DROSU Natalia | United States | The nucleoside analogues zidovudine, tenofovir alafenamide, and cladribine induce EBV lytic gene expression without subsequent viral replication - ID46 View poster - Abstract |
| FRAUSSEN Judith | Belgium |
Increased frequencies of IgD-CD27- double negative (DN) B cells with a pro-inflammatory phenotype and function in MS patients - ID64
|
| GHAZAEIAN Monireh | Iran | Post-marketing experience in the safety profile of Interferon beta‐1b biosimilar product in relapsing-remitting multiple sclerosis: 7 years’ follow-up - ID35 View poster - Abstract - Poster presentation recording |
| HOGLUND Rune Alexander | Norway | CD4+ T cells in the blood of MS patients respond to predicted epitopes from B cell receptors found in spinal fluid - ID27 View poster - Abstract Winner Young Investigator Award |
| KLEIN Julia | Germany |
Medico-economics of therapy decisions in Multiple Sclerosis: switching to ocrelizumab as compared co extending natalizumab intervals - ID23
|
| MAGHZI Amir-Hadi | United States |
Microbiome in Multiple Sclerosis: Role of B-cells and Microglia - ID60
|
| MELNIKOV Mikhail | Russia |
The influence of serotonin on Th17-immune response in multiple sclerosis - ID95
|
| OLIVEIRA Luana | Brazil |
Imaging features of MOG-IgG related disorders: A comparative study with NMOSD - ID77
|
| POLAK Justyna | Poland |
The IGHG1 alleles determine the B cell repertoires in the cerebrospinal fluid of patients with multiple sclerosis - ID82
|
| RADOMIR Lihi | Israel |
Regulating the regulators: the negative fine-tuning of Regulatory B cells by SLAMF5 - ID101
|
| SHARAPKHANOVA Aksholpan | Kazakhstan |
The predicted value of measuring antibodies against John Cunningham virus in patients with multiple sclerosis - ID22
|
| TELESFORD Kiel | United States |
Circulating class-switched antibody-secreting cells are enriched among MS patients self-reporting 'Black African', or 'Latin American/Hispanic' ethnicity relative to those reporting 'Caucasian' ethnicity - ID24
|
| TORSETNES Silje Bøen | Norway |
Assessing immunogenicity of immunoglobulin variable regions - ID100
|
Clinical
| ANDERSEN Louise | Denmark |
Dimethyl Fumarate reduces fatigue in patients with relapsing remitting multiple sclerosis - in a prospective 2 year phase IV trial - ID67
|
| ARALBAYEVA Assel | Kazakhstan | Determining the stage of Parkinson's disease on the scale of Hoehn and Yahr - ID7 View poster - Abstract |
| ARALBAYEVA Assel | Kazakhstan |
Determining cognitive function in Parkinson's disease using a Mini Mental State Examination (MMSE) - ID8
|
| BELETE Daniel | United Kingdom |
Variation in cladribine-induced lymphocyte depletion - ID94
|
| GARCIA Christian Alan | Mexico |
Anti-AQP4 (+) NMO spectrum disorder associated with central nervous system Tuberculosis - ID85
|
| GOMEZ-FIGUEROA Enrique | Mexico |
Pregnancy and Susac Syndrome - ID11
|
| GULDE Philipp | Germany | Towards a quantitative MS assessment - ID38 |
| MILLER Catherine | United States | Diroximel Fumarate Demonstrates Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase 3 EVOLVE-MS-2 Study - ID50 |
| PANTAZOU Vasiliki | Switzerland | Fingolimod versus dimethyl fumarate in first-ever treatment of multiple sclerosis: the Lausanne real-life experience - ID30 |
| PANTAZOU Vasiliki | Switzerland | Recurrence of disease activity after fingolimod discontinuation is not rare in older patients previously stable on treatment - ID31 |
| SAXENA Gauri | United Kingdom | Development of a novel, anti-drug antibody screening platform to detect neutralising responses following alemtuzumab treatment in relapsing multiple sclerosis - ID59 |
| ZABALA Indhira | Mexico | Treatment and follow up of patients with NMO AQP4 seropositive diagnosed in the National Institute of Neurology and Neurosurgery Manuel Velasco Suarez - ID87 |
| ZANETTA Chiara | Italy | Long-term follow up of an Italian coohort of pediatric Multiple Sclerosis patients: real world data from San Raffaele Hospital - ID48 |
Epidemiology
| BEZZINI Daiana | Italy | Mortality trends from Multiple Sclerosis in Italy during the period 1980-2015 - ID15 View poster - Abstract - Poster presentation recording |
| JACOBS Benjamin | United Kingdom |
Body Mass Index and reduced serum vitamin D levels are independent causal risk factors for Multiple Sclerosis: a Mendelian Randomisation study - ID79
|
Investigations
| CACCIAGUERRA Laura | Italy |
White matter myelin alterations are diffuse in Neuromyelitis Optica Spectrum Disorders and prevail on axonal damage - ID51
|
| CHIRIZZI Cristina | Italy |
Multicolor 19F-MRI for in vivo Imaging of immune cells activity in a model of multiple sclerosis - ID69
|
| DE MEO Ermelinda | Italy |
In-vivo mapping of thalamic pathological mechanisms in pediatric patients with MS - ID53
|
| KALININ Ivan | Russia |
Leptomeningeal contrast enhancement is associated with atrophy of subcortical structures in multiple sclerosis: longitudinal study - ID96
|
| KOUBIYR Ismail | France |
Dynamic modular-level alterations of structural–functional coupling in clinically isolated syndrome - ID9
|
| MARENNA Silvia | Italy |
Functional and structural in vivo assessment of demyelination and axonal loss in experimental autoimmune encephalomyelitis mouse model - ID71
|
| MARIANO Romina | United Kingdom |
Spinal Cord Atrophy and Diffusion Tensor Imaging in MOGAD, AQP4-Ab NMOSD & MS - ID66
|
|
PISA Marco
|
Italy |
OCT measures are associated with disease burden and inflammatory biomarkers in newly diagnosed MS and CIS - ID73
|
Treatment
| DALLA COSTA Gloria | Italy |
Serum neurofilament light levels in patients with PPMS following Ocrelizumab treatment - ID99
View poster - Abstract
|
| EGGEBRECHT Julius | Germany |
Assessing the Long-term Outcomes of Ocrelizumab Treatment in Patients with Multiple Sclerosis in Germany – CONFIDENCE Baseline Characteristics - ID61
|
| FERRE Laura | Italy |
Prognostic parameters of medium-term response to fingolimod treatment in Relapsing Remitting Multiple Sclerosis patients - ID90
|
| GOMEZ-FIGERUOA Enrique | Mexico | Clinical evolution in mexican patients with seropositive AQP4 Neuromyelitis optica spectrum disorders treated with rituximab - ID80 |
| HAUSSER-KINZEL Silke | Germany | In multiple sclerosis patients, B cells repopulate immature yet more activated upon anti-CD20 antibody therapy - ID28 |
| IAFFALDANO Antonio | Italy | Early selective depletion of Lymphocyte B subsets and Immune Tolerance restoration in Highly Active Relapsing Multiple Sclerosis patients during Cladribine treatment - ID91 |
| NOVI Giovanni | Italy | Tailoring B-cells depleting therapy in MS according to memory B-cells monitoring: a pilot study - ID49 |
| PALMERI Serena | Italy | Disease activity after alemtuzumab correlates with specific patterns of immune reconstitution in individuals with multiple sclerosis - ID10 |
| PREZIOSA Paolo | Italy | Effects of Fingolimod and Natalizumab on slowly expanding lesion occurence over two years of treatment in relapsing-remitting multiple sclerosis - ID58 |
| TORKE Sebastian | Germany | Inhibition of Bruton’s Tyrosine Kinase Selectively Prevents Antigen-Activation of B cells and Ameliorates B cell-Mediated Experimental Autoimmune Encephalomyelitis - ID36 |
| ZANETTA Chiara | Italy | Late onset absolute neutropenia following ocrelizumab treatment in Multiple Sclerosis - ID92 |
